Melanoma and epigenetic treatment: Past and future

Anti-Cancer Agents in Medicinal Chemistry

Volumn 12, Issue 3, 2012, Pages 202-209

  la Porta, Caterina A M ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Epigenetic; Melanoma; MicroRNAs

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALPHA INTERFERON; BELINOSTAT; DACARBAZINE; DAZACARBINE; DOCETAXEL; ENTINOSTAT; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 2; MICRORNA; PANOBINOSTAT; PEGINTERFERON ALPHA2B; PREDNISONE; ROMIDEPSIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; DNA METHYLATION; DRUG HALF LIFE; EPIGENETICS; GENE CONTROL; GENE DELETION; GENE EXPRESSION; GENE REPRESSION; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HISTONE MODIFICATION; HUMAN; LYMPHOMA; MELANOMA; NONHUMAN; PROTEIN PROCESSING; SOLID TUMOR; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 84857706554     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152012800228760     Document Type: Article

References (106)

1. Bard, M.; Woods, R.A.; Bartón, D.H.; Corrie, J.E.; Widdowson, D.A. Sterol mutants of Saccharomyces cerevisiae: chromatographic analyses. Lipids, 1977, 12(8), 645-654.
2. de Vries, E.; Bray, F.I.; Coebergh, J.W.; Parkin, D.M. Changing epidemiology of malignant cutaneous melanoma in Europe 1953-1997: rising trends in incidence and mortality but recent stabilizations in western Europe and decreases in Scandinavia. J. Cancer, 2003, 107(1), 119-126.
3. MacKie, R.M.; Bray, C.A.; Hole D.J.; Morris A.; Nicolson M.; Evans A.; Doherty V.; Vestey J.; Scottish melanoma Group. Incidence of and survival from malignant melanoma in Scotland: an epidemiological study. Lancet, 2002, 360(9333), 587-591.
4. Jemal, A.; Murray, T.; Samuels, A.; Ghafoor, A.; Ward, E.; Thun, M.J. Cancer statistics CA, Cancer J. Clin., 2003, 53(1), 5-26.
5. Morton, D.L.; Essner, R.; Calch, C. Surgical excision of distant metastasis. In: Bach C, Houghton A, Sober A, et al., Editors Cutaneous melanoma 4th ed. St Louis (MO): Quality Medical Publishing, 2003, 547-572.
6. Balch, C.M.; Buzaid, A.C.; Soong, S-J.; Atkins M.B.; Cascinelli N.; Coit D.G.; Fleming I.D.; Gershenwald J.E.; Houghton A. Jr; Kirkwood J.M.; McMasters K.M.; Mihm M.F.; Morton D.L.; Reintgen D.S.; Ross M.I.; Sober A.; Thompson J.A.; Thompson J.F. Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma. J. Clin. Oncol., 2001, 19, 3635-3648.
7. Middleton, M.R.; Lorigan P.; Owen J.; Ashcroft L.; Lee S.M.; Harper P.; Thatcher N. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. Br J. Cancer, 2000, 82(6), 1158-1162.
8. Luikart, S.D., Kennealey, G.T., Kirkwood, J.M. Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammineplatinum versus dacarbazine in malignant melanoma. J. Clin. Oncol., 1984, 2(3), 164-168.
9. Chapman, P.B.; Saxman S.; Destro A.N.; Panageas K.S.; Begg C.B.; Agarwala S.S.; Schuchter L.M.; Ernstoff M.S.; Houghton A.N.; Kirkwood J.M. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J. Clin. Oncol., 1999, 17(9), 2745-2751.
10. Middleton, M.; Lorigan, P.; Owen, J.; Ashcroft, L., Lee S.M., Harper P., Thatcher N. A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. Br. J. Cancer, 2000, 82(6), 1158-1162.
11. Klose, R.J.; Bird, A.P. Genomic DNA methylation: the mark and its mediators. Trends Biochem. Sci., 2006, 31(2), 89-97.
12. Bestor, T.H.; Verdine, G.L. DNA methyltranferases. Curr. Opin. Cell Biol., 1994, 6(3), 380-389.
13. Li, E.; Bestor, T.H.; Jaenisch, R. Targeted mutation in the DNA methyltransferase gene results in embryonic lethality. Cell, 1992, 69(6), 915-926.
14. Struhl, K. Histone acetylation and transcriptional regulatory mechanisms. Genes Dev., 1998, 12(5), 599-606.
15. Straha, B.D.; Allis, C.D. The language of covalent histone modifications. Nature, 2000, 403(6765), 41-45.
16. Taby, R., Issa, J.J. Cancer epigenetics. Cancer J. Clinical, 2010, 60(6), 376-392
17. Schones, D.E.; Cui, K.; Cuddapah, S.; Roh T.Y., Barski, A.; Wang, Z.; Wei, G; Zhao, K. Dynamic regulation of nucleosome positioning in the human genome. Cell, 2008, 132 (5), 887-898.
18. Ghildiyal, M.; Zamore, P.D. Small silencing RNAs:an expanding universe. Nat. Rev. Genetic, 2009, 10 (2), 94-108.
19. Lim, L.P.; Lau, N.C.; Garrett, E.P.; Grimson, A; Schelter, J.M.; Castle, J.; Bartel, D.P.; Linsley, P.S.; Johnson, J.M. Microarray analysis shows that some microRNAs downregulate large numbers of target miRNAs. Nature, 2005, 453 (7027), 769-773.
20. Jones, P.A.; Baylin, S.B. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med., 2003, 350(9), 947-948.
21. Furuta, J.; Umebayashi, Y.; Miyamoto, K.; Kikuchi, K.; Otsuka, F.; Sugimura, T.; Ushijima, T. Promoter methylation profiling of 30 genes in human malignant melanoma. Cancer Sci., 2004, 95(12), 962-968.
22. Hoon, D.S.; Spugnardi, M.; Kuo, C.; Huang, S.K.; Morton, D.L.; Taback, B. Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene, 2004, 23(22), 4014-4022.
23. Farmer, E.R.; Gonin, R.; and Hanna, M.P. Discordance in the histopathologic diagnosis of melanoma and melanocytic nevi between expert pathologists. Hum. Pathol., 1996, 27(6), 528-531.
24. Conway, K.; Edmiston, S.N.; Khondker, Z.S.; Groben, P.A.; Zhou, X.; Chu H.; Kuan P.F.; Hao, H.; Carson C.; Berwick, M.; Olilla, D.W.; Thomas, N.E. 2,6(DNA-methylation profiling distinguishes malignant melanomas from benign nevi. Pigment Cell Melanoma Res., 2011, 24(2), 352-360.
25. Liu, S.; Ren, S.; Howell, P.; Fodstad, O.; Riker, A.L. Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling. Pigment Cell Melanoma Res., 2008, 21(5), 545-558.
26. Sigalotti, L.; Coral, S.; Nardi, G.; Spessotto, A.; Cortyini, E.; Cattarossi, I.; Colizzi, F.; Altomonte, M,; Maio, M. Promoter methylation controls the expression of MAGE2, 3 and 4 genes in human cutaneous melanoma. J. Immunother., 2002, 25(1), 16-26.
27. Luo, W.; Wang, X.; Kageshita, T.; Wakasugi, S.; Karpf, A.R.; Ferrone, S. Regulation of high molecular weight-melanoma associated antigen (HMW-MAA) gene expression by promoter DNA methylation in human melanoma cells. Oncogene, 2006, 25(20), 2873-2884.
28. James, S.R., Link, P.A., Karpf, A.R. Epigenetic regulation of Xlinked cancer/ germline antigen genes by DNMT1 and DNMT3b. Oncogene, 2006, 25(52), 6975-6985.
29. Wada, K.; Maesawa, C.; Akasaka, T.; Masuda T. Aberrant expression of the maspin gene associated with epigenetic modification in melanoma cells. J. Invest. Dermatol., 2004, 122(3), 805-811.
30. Ushijima, U.; Okochi-Takada E. Aberrant methylations in cancer cells: Where do they come from? Cancer Sci 2005; 96(4): 206-211.
31. Simpson, A.J.; Caballero, O.L.; Jungbluth, A.; Chen, Y.T.; Old, L.J. Cancer/testis antigens, gametogenesis and cancer. Nat. Rev. Cancer, 2005, 5(8), 615-625.
32. Taghizadeh, R.; Noh, M.; Huh, Y.H.; Ciusani, E.; Sigalotti, L.; Maio, M.; Arosio, B.; Nicotra, M.R.; Natali, P.G.; Sherley, L.J.; La Porta, C.A.M. CXCR6, a newly defined biomarker of tissuespecific stem cell asymmetric self-renewal, identifies more aggressive human melanoma cancer stem cells, PLoS ONE, 2010, 5(12): e15183.
33. Alcazar, O.; Achbarger, S.; Aldrich, W.; Hu, Z.; Negrotto, S.; Santharara Jah, Y.; Trozzi, P. Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo. Int. J. Cancer, 2011, doi: 10.1002/ijc.26320.
34. Mazar, J.; Deblasio, D.; Govindarajan, S.S.; Zhang, S.; Perera, R.J. Epigenetic regulation of microRNA-375 and its role in melanoma development in humans, Febs. Lett., 2011, 585(15), 2467-2476.
35. Mologrovi F, Cruz AT, Meliso FM, Marais AS, Sonza CF, Xander P, Bishop JM, Costa FF, Soares MB, Liang G, Jones PA, Jasiulionis MG, Epigenetic reprogammring as a key contributor to melanocyte malignant transformation. Epigenetics, 2011, 6(4), 450-464.
36. Kapoor, A.; Goldberg, M.S.; Cumberland, L.K.; Ratnakumar, K.; Segura, MF.; Emanuel, P.O.; Menendez, S.; Vardabasso, C.; LeRoy, G.; Vidal, C.I.; Polsky, D.; Osman, I.; Garcia, B.A.; Hernando, E.; Bernstein, E. The histone variant macroH2A suppresses melanoma progression through regulation of CDK8. Nature, 2010, 468 (7327), 1105-1109.
37. Ito, A.; Kawaguchi, Y.; Lai, C.H.; Kovacs, J.J.; Higashimoto, Y.; Appella, E.; Yao, T.P. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J, 2002, 21(22), 6236-6245.
38. Lang, S.; Ma, Y.; Liu, D. New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer. J. Hematol. Oncol., 2009, 9(1), 22.
39. Martinet, N.; Bertrand, P. Interpreting clinical assays for histone deacetylase inhibitors. Cancer Manag. Res., 2011, 3(9), 117-141.
40. Nihal, N.; Roelke, C.T.; Wood, G.S. Anti-melanoma effects of vorinostat in combination with polyphenolic antioxidant(+)- epigallocatechin-3-gallate (ECGC). Pharm. Res., 2010 27(6), 1103-1114
41. Munster, P.N.; Marchion, D.; Thomas, S.; Egorin, M.; Minton, S.; Springett, G.; Lee, J-H.; Simon, G.; Chiappori, A.; Sullivan, D.; Daud, A. Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Br. J. Cancer, 2009, 101(7), 1044-1050.
42. Minucci S.; Pelicci, P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Revi. Cancer, 2006, 6(1), 38-51.
43. Qian, D.Z.; Kato, Y.; Shabbeer, S.; Wei, Y.; Berheul, H.M.; Salumbides, B.; Sanni, T.; Atadja, P.; Pili R. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin. Cancer Res., 2006, 12(2), 634-642.
44. Carew, J.S.; Giles, F.J.; Nawrocki, S.T. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett. 2008, 269(1), 7-17.
45. Magnaghi-Jaulin, L.; Eot-Houllier, G.; Fulcrand, G.; Jaulin, C. Histone deacetylase inhibitors induce premature sister chromatid separation and override the bmitotic spindle assembly checkpoint. Cancer Res., 2007, 67(13), 6360-6367.
46. Shao, Y.; Gao, Z.; Marks, P.A.; Jiang, X. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc. Natl. Acad Sci. USA, 2004, 101(52), 18030-18035.
47. Xu, W.S.; Perez, G.; Ngo, L.; Gui, C.Y.; Marks, P.A. Induction of polyploidy by histone deacetylase inhibitor: a pathway for antitumor effects. Cancer Res., 2005, 65(17), 7832-7839.
48. Facchetti, F.; Previdi, S.; Ballarini, M.; Minucci, S.; Perego, P.; La Porta C.A. Modulation of pro- and antiapoptoticfactors in human melanoma cells exposed to histone deacetylase inhibitors. Apoptosis, 2004, 9(5), 573-582.
49. Zhang, X.D.; Gillespie, S.K.; Borrow, J.M.; Hersey, P. The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells. Mol Cancer Ther. 2004, 3(4), 425-435.
50. Flørenes, V.A.; Skrede, M.; Jørgensen, K.; Nesland, J.M. Deacetylase inhibition in malignant melanomas: impact on cell cycle regulation and survival. Melanoma Res., 2004, 14(3), 173-181.
51. Bandyopadhyay, D.; Mishra, A.; Medrano, E.E. Overexpression of of histone deacetylase 1 confers resistance to sodium butyratemediated apoptosis in melanoma cells through a p53-mediated pathway. Cancer Res., 2004, 64(21), 7706-7710.
52. Soengas, M.S.; Capodieci, P.; Polsky, D.; Mora, J.; Esteller, M.; Opiz-Araya, X; Herman, J.G.; Gerald W.L., Lazebnik, Y.A.; Cordon-Cardo, C.; Lowe, S.W. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature, 2001, 409(6817), 207-211.
53. Peart, M.J.; Smyth, G.K.; van Laar, R.K.; Bowtell, D.D.; Richon, V.W.; Marks, P.A.; Holloway, A.J.; Johnstone, R.W. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc. Natl. Acad. Sci. USA, 2005, 102(10), 3697-3602.
54. Kobayashi, Y.; Ohtsuki, M.; Murakami, T.; Sutheesophon, K.; Kitayama, H; Kano, Y.; Kusano, E.; Nakagawa, H.; Furukawa, Y. Histone deacetylase inhibitor FK228 suppresses the Ras-MAP kinase signaling pathway by upregulating Rap1 and induces apoptosis in malignant melanoma. Oncogene, 2006, 25(4), 512-524.
55. Munshi, A.; Tanaka, T.; Hobbs, M.L.; Tucker, S.L.; Richon, V.M., Meyn, R.E. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol. Cancer Ther., 2006, 5(8), 1967-1974.
56. Lee, H.S.; Park, M.H.; Yang, S.J.; Jung, H.J.; Byun, S.S.; Lee, D.S.; Yoo, H.S.; Yeom, Y.I.; Seo, S.B. Gene expression analysis in human gastric cancer cell line treated with trichostatinA and Sadenosyl- L-homo - cysteine using cDNA microarray. Biol. Pharm. Bull., 2004, 27(10), 497-503
57. Hess-Stumpp H.; Bracker, T.U.; Henderson, D.; Politz, O. MS-275, a potent orally available inhibitor of histone deacetylases: the development of an anticancer agent. Int. J. Biochem. Cell Biol., 2007, 39(7-8), 1388-1405.
58. Milutinovic, S.; D'Alessio, A.C.; Detich, N.; Szyf, M. Valproate induces widespread epigenetic reprogramming which involves demethylation of specificgenes. Carcinogenesis, 2007, 28(3), 560-571.
59. Khan, A.N.; Gregorie, C.J.; Tomasi, T.B. Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells. Cancer Immunol. Immunother., 2008, 57(5), 647-654.
60. Pruitt, K.; Zinn, R.L.; Ohm, J.E.; McGarvey, K.M.; Kang, S.H.; Watkins, D.N.; Herman, J.G.; Baylin, S.B. Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet., 2006, 2(3), e40.
61. Ou, J.N.; Torrisani, J.; Unterberger, A.; Provencial N.; Shikimi, K.; Karimi, M.; Ekstrom, T.J., Szyf, M. Histone deacetylase inhibitor Trichostatin A induces global and gene-specific DNA demethylation in human cancer cell lines. Biochem. Pharmacol., 2007, 73(9), 1297-1307.
62. Wu, L.P.; Wang, X.; Li, L.; Zhao, Y.; Lu, S.; Yu, Y.; Zhou, W.; Liu, X.; Yang, J.; Zheng, H.; Feng, J.; Yang, Y.; Wang, H.; Zhu, W.G. Histone deacetylase inhibitor depsipeptide activates silenced genes through decreasing both CpG and H3K9 methylation on the promoter. Mol. Cell Biol., 2008, 28(10), 3219-3235.
63. Gore, L.; Rothenberg, M.L.; O'Bryant, C.L.; Schultz, M.K.; Sander, A.B.; Coffin, D.; McCoy, C.; Schott, A.; Scholz, C.; Eckhardt, S.G. A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin. Cancer Res., 2008, 14(14), 4517-4525.
64. Kuwajima, A.; Iwashita, J.; Murata, J.; Abe, T.The histone deacetylase inhibitor butyrate inhibits melanoma cell invasion of Matrigel. Anticancer Res., 2007, 27(6B), 4163-4169.
65. Lacreusette, A.; Nguyen, J.M.; Pandolfino, M.C.; Khammari, A.; Dreno, B.; Jacques, Y.; Godard, A.; Blanchard, F. Loss of oncostatin M receptor beta in metastatic melanoma cells. Oncogene, 2007, 26(6), 881-892.
66. Valentini, A.; Gravina, P.; Federici, G.; Bernardini, S. Valproic acid induces apoptosis, p16INK4A upregulation and sensitization to chemotherapy in human melanoma cells. Cancer Biol. Ther., 2007, 6(2), 185-191.
67. Chinnaiyan, P.; Varambally, S.; Tomlins, S.A.; Ray, S.; Hunag, S.; Chinnaiyan, A.M.; Harari, P.M. Enhancing the antitumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition. Int. J. Cancer, 2006, 118(4), 1041-1050.
68. Moore, P.S.; Barbi, S.; Donadelli, M.; Costanzo, C.; Bassi, C.; Palmieri, M.; Scarpa, A. Gene expression profiling after treatment with the histone deacetylase inhibitor trichostatin A reveals altered expression of both pro- and anti-apoptotic genes in pancreatic adenocarcinoma cells. Biochim. Biophys. Acta, 2004, 1693(3), 167-176.
69. Glaser, K.B.; Staver, M.J.; Waring, J.F.; Stender, J.; Ulrich, R.G.; Davidsen, S.K. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol. Cancer Ther., 2003, 2(2), 151-163.
70. Sasakawa, Y.; Naoe, Y.; Sogo, N.; Inoue, T.; Sasakawa, T.; Matsuo, M., Manda, T., Mutoh, S. Marker genes to predict sensitivity to FK228, a histone deacetylase inhibitor. Biochem. Pharmacol., 2005, 69(4), 603-616.
71. Maelandsmo, G.M.; Holm, R.; Fodstad, O.; Kerbel, R.S., Florenes, V.A. Cyclin kinase inhibitor p21WAF1/CIP1 in malignant melanoma: reduced expression in metastatic lesions. Am. J. Pathol., 1996, 149(6), 1813-1822.
72. Kato, Y.; Salumbides, B.C.; Wang, X.F.; Qian, D.Z.; Williamns, S.; Wie, Y.; Sanni, T.B.; Atadja, P.; Pili, R. Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cisretinoic acid in human malignant melanoma. Mol. Cancer Ther., 2007, 6(1), 70-81.
73. Koh, E.; Bandle, R.; Clair, T.; Roberts, D.D.; Stracke, M.L. Trichostatin A and 5-aza-2'-deoxycytidine switch S1P from an inhibitor to a stimulator of motility through epigenetic regulation of S1P receptors. Cancer Lett., 2007, 250(1), 53-62.
74. Lehman, J.M.; Riethmuller, G.; Johnson, J.P. MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc. Nati. Acad. Sci., 1989, 86(24), 9891-9895.
75. Johnson, J.P.; Bar-Eli, M.; Jansen, B.; Markhof, E. Melanoma progression-associatedglycoprotein MUC18/MCAM mediates homotypic cell adhesion through interaction with a heterophilic ligand, Int. J. Cancer, 1997, 73(5), 769-774.
76. Bardin, N.; Anfosso, F.; Masse, J.M.; Cramer, E.; Sabatier, F.; Le Bivic, A.; Sampol, J.; Dignat-George, F. Identification of CD146 as a component of the endothelial junction involved in the control of cell-cell cohesion. J. Biol. Chem., 2001, 98(13), 3677-3684.
77. Drancourt, M.; George, F.; Brouqui, P.; Sampol, J.; Raoult, D. Diagnosis of Mediterranean spotted fever by indirect immunofluorescence of Rickettsia conorii in circulating endothelial cells isolated with monoclonal antibody-coated immunomagnetic beads. J. Infect Dis., 1992, 166(3), 660-663.
78. George, F.; Brouqui, P.; Boffa, M.C.; Mutin, M.; Drancourt, M.; Brisson, C.; Raoult, D.; Sampol, J. Demonstration of Rickettsia conorii-induced endothelial injury in vivo by measuring circulating endothelial cells, thrombomodulin, and von Willebrand factor in patients with Mediterranean spotted fever. Blood, 1993, 82(7), 2109-2116.
79. Mutin, M.; Canavy, I.; Blann, A.; Bory, M.; Sampol, J.; Dignat- George, F. Direct evidence of endothelial injury in acutemyocardial infarction and unstable angina by demonstration of circulating endothelial cells. Blood, 1999, 93(9), 2951-2958.
80. Solovey, A.N.; Gui, L.; Chang, L.; Enenstein, J.; Browne, P.V.; Hebbel, R.P. Identification and functional assessment of endothelial P1H12. J. Lab. Clin. Med., 2001, 138(5), 322-331.
81. Li, Q.; Yu, Y.; Bischoff, J.; Mulliken, J.B.; Olsen, B.R. Differential expression of CD146 in tissues and endothelial cells derived from infantile haemangioma and normal human skin. J. Pathol., 2003, 201(2), 296-302.
82. Bardin, N.; Moal, V.; Anfosso, F.; Daniel, L.; Brunet, P.; Sampol, J.; Dignat F. G. Soluble CD146, a novel endothelial marker, is increased in physiopathological settings linked to endothelial junctional alteration. Thromb. Haemost., 2003, 90(5), 915-920.
83. Bolton, C.H.; Downs, L.G.; Victory, J.G.; Dwight, J.F.; Tomson, C.R.; Mackness, M.I.; Pinkney, J.H. Endothelial dysfunction in chronic renal failure: roles of lipoprotein oxidation and proinflammatory cytokines. Nephrol. Dial Transplant., 2001, 16(6), 1189-1197.
84. St Croix, B.; Rago, C.; Velculescu, V.; Traverso, G.; Romans, K.E.; Montgomery, E. Lal, A.; Riggins, G.J.; Lengauer, C.; Vogelstein, B.; Kinzler, K.W. Genes expressed in human tumor endothelium. Science, 2000, 289(5482), 1197-1202.
85. Shih, L.M.; Hsu, M.Y.; Palazzo, J.P.; Herlyn, M. The cell-cell adhesion receptor Mel- CAM acts as a tumor suppressor in breast carcinoma. Am. J. Pathol,. 1997, 151(3), 745-751.
86. Luca, M.; Hunt, B.; Bucana, C.P.; Johnson, J.P.; Fidler, I.J.; Bar-Eli, M. Direct correlation between MUC18 expression and metastatic potential of human melanoma cells, Melanoma Res., 1993, 3(1), 35-41.
87. Li, G.; Satyamoorthy, K.; Herlyn, M. Dynamics of cell interactions and communications during melanoma development. Crit. Rev. Oral Biol. Med., 2002, 13(1), 62-70.
88. J.P. Cell adhesion molecules in neoplastic disease. Int. J. Clin Lab. Res., 1992, 22,(2) 69-72.
89. Bani, M.R.; Rak, J.; Adachi, D.; Wiltshire, R.; Trent, J.M.; Kerbel, R.S.; Ben-David, Y. Multiple features of advanced melanoma recapitulated in tumorigenic variants of early stage (radial growth phase) human melanoma cell lines: evidence for a dominant phenotype. Cancer Res., 1996, 56(13), 3075-3086.
90. Xie, S.; Luca, M.; Huang, S.; Gutman, M.; Reich, R.; Johnson, J.P.; Bar-Eli, M. Expression of MCAM/MUC18 by human melanoma cells leads to increased tumor growth and metastasis. Cancer Res., 1997, 57(11), 2295-2203.
91. Satyamoorthy, K.; Muyrers, J.; Meier, F.; Pate, D.; Herlyn, M. Mel-CAM-specific genetic suppressor elements inhibit melanoma growth and invasion through loss of gap junctional communication. Oncogene, 2001, 20(34), 4676-4684.
92. McGary, E.C.; Heimberger, A.; Mills, L.; Weber, K.; Thomas, G.W.; Shtivelband, M.; Lev, M.; Bar-Eli, M. A fully human antimelanoma cellular adhesion molecule/MUC18 antibody inhibits spontaneous pulmonary metastasis of osteosarcoma cells in vivo, Clin. Cancer Res., 2003, 9(17), 6560-6566.
93. Melnikova, V.O.; Bar-Eli, M. Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL-8. Pigment Cell Res., 2006, 19(5), 395-405.
94. Leslie, M.C.; Zhao, Y.J.; Lachman, L.B.; Hwu, P.; Wu, G.-J.; Bar-Eli, M. Immunization against MUC18/MCAM, a novel antigen that drives melanoma invasion and metastasis. Gene Ther., 2007, 14(4), 316-323.46
95. Zigler, M.; Villares, G.J.; Lev, D.C.; Bar-Eli, M. Tumor immunotherapy in melanoma: strategies for overcoming mechanisms of resistance and escape. Am. J. Clin Dermatol., 2008, 9(5), 307-311.
96. Schultz, J.; Lorenz, P.; Gross, G.; Ibrahim, S.; Kunz, M. MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorageindependent growth. Cell Res., 2008, 18, 549-557.
97. Mueller, D.W., Rehli, M., Bosserhoff, A.K. miRNA expression profiling in melanocytes and melanoma cell lines reveals miRNAs associated with formation and progression of malignant melanoma. J. Invest. Dermatol., 2009, 129, 1740-1751.
98. Segura, M.F.; Hanniford, D.; Menendez, S.; Reavie, L.; Zou, X.; Alvarez-Diaz, S.; Zakrzewski, J.; Blochin, E.; Bogunovic, D.; Polsky, D.; Wei, J.; Lee, P.; Belitskaya-Levy, I.; Bhardwaj, N.; Osman, I.; Hermando, E. Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmiaassociated transcription factor. Proc. Natl. Acad. Sci. USA, 2009, 106(6), 1814-1819.
99. Caramuta, S.; Egyhazi, S.; Rodolfo; M.; Witten, D.; Hansson, J.; Larsson, C.; Lui, W.O. MicroRNA expression profiles associated with mutational status and survival in malignant melanoma. J. Invest. Dermatol., 2010, 130(8), 2062-2070.
100. Chen, J.; Feilotter, H.E.; Pare, G.C.; Zhang, X.; Pemberton, J.G.; Garady, C.; Lai, D.; Yang, X.; Tron, V.A. MicroRNA-193b represses cell proliferation and regulates cyclin D1 in melanoma. Am. J. Pathol., 2010, 176(5), 2520-2529.
101. Mueller, D.W.; Bosserhoff, A.K. Role of miRNAs in the progression of malignant melanoma. Br. J. Cancer, 2009, 101(4), 551-556.
102. Segura, M.F.; Belitskaya-Levy, I.; Rose, A.E. Zakrzewski, J.; Gaziel, A.; Hanniford, D.; Darvishian, F.; Berman, R.S.; Shapiro, R.L.; Pavlick, A.C.; Osman, I.; Hernando, E. Melanoma MicroRNA signature predicts postrecurrence survival. Clin. Cancer Res., 2010, 16(5), 1577-1586.
103. Philippidou, D., Schmitt, M., Moser, D.; Margue, C.; Nazarov, P.V.; Muller, A.; Vallar, L.; Nashan, D.; Bermann, I.; Kreis, S.Signatures of microRNAs and selected microRNA target genes in human melanoma. Cancer Res. 2010, 70(10), 4163-4173.
104. Chan, E.; Patel, R.; Nallur, S.; Ratner, E.; Bacchiocchi, A.; Hoyt, K.; Szpakowski, S.; Godshalk, S.; Ariyan, S.; Sznol, M.; Halaban, R.; Krauthmmer, M.; Tuck, D.; Slack, F.J.; Weidhaas, J.B. Signature of microRNAs and selected microRNA target genes in human melanoma. Cell Cycle, 2011, 10(11), 1845-1852.
105. Greenberg, E.; Hershkovitz, L.; Itzhaki, O.; Haidu, S.; Nemlich, Y.; Ortenberg, R.; Gefen, N.; Edry, L.; Modai, S.; Keisari, Y.; Besser, M.J.; Schachter, J.; Shomron, N.; Markel, G. Regulation of cancer aggressive features in melanoma cells by microRNAs, Plos One 2011, 25, 6(4), e18936.
106. Schneider, M.R. miRNAs as novel players in skin development, homeostasis and disease. Br. J. Dermatol., 2011, doi: 10.1111/ j.1365-2133.2011.10568.x.